Crinetics Pharmaceuticals (CRNX) just unveiled an announcement.
Crinetics Pharmaceuticals, Inc. has announced promising preliminary results from a Phase 2 study of paltusotine for treating carcinoid syndrome, a significant stride in developing treatments for acromegaly and carcinoid syndrome. The company will share the full details with the FDA to discuss the progression to Phase 3 trials. Investors and interested parties can access the release and further details through the company’s website and an upcoming conference call and webcast. However, these forward-looking statements are subject to risks and uncertainties, and the results may change upon a detailed review or regulatory feedback.
For a thorough assessment of CRNX stock, go to TipRanks’ Stock Analysis page.
